Results 341 to 350 of about 174,356 (352)

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Cancer Cell, 2010
Jessie Villanueva, Adina Vultur, Damien Kee   +2 more
exaly  

The evolving landscape of tissue‐agnostic therapies in precision oncology

Ca-A Cancer Journal for Clinicians
Vivek Subbiah, Bettina Ryll, Razelle Kurzrock   +2 more
exaly  

Hochgebohrner Braf

2000
openaire   +1 more source

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Nature Reviews Clinical Oncology
Ziyu Chen, David B Solit
exaly  

High frequency of BRAF mutations in nevi

Nature Genetics, 2002
Pamela M Pollock, Mitchell S Stark, John W Kakareka   +2 more
exaly  

BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications

Endocrine Reviews, 2007
Mingzhao Xing
exaly  

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Lancet, The, 2015
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas   +2 more
exaly  

Vemurafenib: the first drug approved for BRAF-mutant cancer

Nature Reviews Drug Discovery, 2012
exaly  

BRaf-Signaling

2017
openaire   +1 more source

BRAF Mutations

2016
openaire   +1 more source